Lin Wu

1 month ago | nature.com | Yuxiang Ma |Yun Fan |Siqing Fu |Lin Wu |David Sommerhalder |Wei Lian | +2 more

AbstractAntibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker.

Nov 5, 2024 | mdpi.com | Xiaoyu Yang |Ying Liu |Lin Wu |Zhiyuan Liao

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Nov 4, 2024 | onlinelibrary.wiley.com | Lin Wu

BOOK REVIEW TikTok Broadway: Musical theater fandom in the digital age By Trevor Boffone, New York: Oxford University Press. 2024. pp. 232. $34.95 (hbk) First published: 04 November 2024 No abstract is available for this article.

Aug 21, 2024 | nature.com | Lin Wu |Qian Chu

AbstractThis single-arm, multicenter, phase 2 trial (NCT04106180) investigated the triple combination of sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic non-small cell lung cancer (NSCLC). With a median follow-up of 32.1 months, 18 (36.7%, 90% CI 25.3%–49.5%) of the 49 evaluable patients had an objective response, meeting the primary endpoint.

Aug 3, 2024 | mdpi.com | Bo Wang |Lin Wu |Pengfei Wu |Qianqian Li

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.